Thus, Pusch et al. provided evidence that the pan-mutant IDH inhibitor BAY1436032 was able at a 70 mg/kg dose to prolong the survival of nude mice xenografted intracranially with IDH1-mutant glioma cells [400]. This evidence concerns the gene IDH1 and central nervous system cancer.